Can SkyePharma PLC (+78%), Cairn Energy PLC (+63%) And Vedanta Resources plc (+56%) Keep On Climbing?

Are SkyePharma PLC (LON: SKP), Cairn Energy PLC (LON: CNE) And Vedanta Resources plc (LON: VED) set for big wins?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceuticals, oil and gas exploration, and mining — quite a heady combination these days, but all three shares have been rising strongly of late and could have much further to go.

Look at SkyePharma (LSE: SKP). Its shares have climbed by 78% from their 52-week low in August 2015, to 457p — and if that’s not enough for you, over the past five years they’ve soared by a massive 990%! But, can it keep going?

I’d say there’s a very good possibility that it can. SkyePharma, once a lossmaking blue-sky possibility, has crossed the line into profitability and earnings per share (EPS) have been swelling nicely. In fact, though there’s a fall in EPS forecast for this year, the subsequent growth pencilled-in for 2017 would put the shares on a P/E of a little over 15 — and I reckon that’s very attractive for a growth candidate.

What’s more, SkyePharma’s speciality is in developing drug delivery technology rather than the drugs themselves — things like oral, topical, inhalable and injectable delivery systems. And to me that makes the firm look like a lower risk “picks and shovels” candidate, whose products are used by big-name drug developers including GlaxoSmithKline, Novartis, Roche and others.

Oil strength

The rising price of oil, which is oscillating around the $40 level, has helped boost Cairn Energy (LSE: CNE) shares by 63% to 208p since their low of 20 January. Full-year results released on 15 March contributed too. Chief executive Simon Thomson said of the firm’s offshore Senegal prospects that the results have confirmed “the scale and extent of the significant resource base in this world class asset“.

A risk with Cairn Energy is that it’s still at the cash-burn stage and there are no profits within the forecast horizon yet. But at 31 December there was a tidy $603m net cash on the books, and the company still has undrawn lending facilities and letters of credit that should add around another $500m to its available cash. Cairn, then, isn’t going to be hit by the kind of debt squeeze in the near future that some of its rivals will face.

With some impressive assets under development and a positive brokers’ stance, Cairn looks promising to me.

Mining resurgence

India-focused Vedanta Resources (LSE: VED) has seen its shares drop 41% over the past 12 months as the commodities slump has continued to bite, but since a low on 18 January there has been a 56% climb to 320.5p. With the firm’s main products being copper, zinc, aluminium, lead, iron ore and petroleum, the recent recoveries in minerals and oil prices have both given the shares a leg up.

Vedanta, like the rest of the sector, isn’t out of the woods yet. With earnings having plummeted over the past few years, the company has three years of losses forecast — and its dividend, set to yield 4.5% for the year to March 2016, is surely not going to be maintained.

But the losses should be relatively small, and the long-term future is surely solid, even if analysts currently have Vedanta as a sell.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

Here’s how I’m trying to prevent a stock market crash from ruining my portfolio

Jon Smith explains which shares he's avoiding and what he's thinking of buying to try and protect his portfolio from…

Read more »

Bearded man writing on notepad in front of computer
US Stock

Call me crazy, but here’s why I’m eyeing up the CrowdStrike share price

Jon Smith notes the carnage caused by Friday's global outage, but flags up why he's thinks the CrowdStrike share price…

Read more »

Investing Articles

What do Hargreaves Lansdown results mean for the share price?

The Hargreaves Lansdown share price has surged in recent months on takeover expectations, but what will the recent results mean…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Newly minted S&P 500 stock CrowdStrike just crashed! Here’s why

Shares of S&P 500 firm CrowdStrike collapse as the company lies at the centre of a global IT outage. What…

Read more »

artificial intelligence investing algorithms
Investing Articles

Is Nvidia heading for the mother of all tech stock crashes?

Nvidia stock has soared, and the company briefly became the most valuable on the planet. But not everyone’s an AI…

Read more »

Dividend Shares

The BP share price is down 15% in 3 months. Time to buy?

In the space of just a few months, the BP share price has fallen by a double-digit percentage. Is this…

Read more »

Investing Articles

A 5.4% dividend bargain I’ll buy over Lloyds shares

Harvey Jones loves his Lloyds shares but now he's found a high-yielding FTSE 250 stock that may offer even more…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Recommended by Warren Buffett, this top hedge fund’s betting on Rolls-Royce shares

When Warren Buffett ended his previous investment partnership, he recommended Bill Ruane’s Sequoia Fund. Today, its largest investment is in…

Read more »